Company Description
BioLife4D Corporation is a pioneering biotech company that plans to leverage current advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation – potentially lifesaving technology that ultimately gives patients the gift of time.
We are committed to perfecting the technology to make viable organ replacement an accessible and affordable reality, as well as mini-hearts for cardiotoxicity testing.
We believe that our groundbreaking approach converges recent breakthroughs in regenerative medicine, adult stem cell biology, 3D printing techniques, and computing technology that could make organ replacement commercially viable and commonplace globally.
We plan to create a patient-specific, fully functioning heart through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
We will not have to make an exact copy or even recreate every feature set of the desired organ; it will only need to facilitate the minimum feature set which recreates the core properties of the organ.
It is important to note that we do not believe we need to invent new technology, but rather improve, adopt, and optimize current technologies to create what we plan to be a commercially viable and sustainable process.
We seek to improve, optimize, adapt, and capitalize on current technologies to create a commercially viable and sustainable process solution.
| Country | United States |
| Founded | 2016 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 7 |
| CEO | Steven Morris |
Contact Details
Address: 318 Half Day Road, Suite 201 Buffalo Grove, IL 60089 United States | |
| Phone | (224) 602-9569 |
| Website | biolife4d.com |
Stock Details
| Ticker Symbol | SAVU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001714919 |
| Employer ID | 81-4586116 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven Morris | Chief Executive Officer, Secretary, and Chairman of our Board of Directors |
| Kate Lewis | President |
| Wesley Ramjeet | Chief Financial Officer |
| Dr. Jeffrey Morgan | Chief Medical Officer |
| Stephen Simes | Director |
| Lisa Kelley | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2023 | 1-SA | Filing |
| Jun 20, 2023 | FWP | Free Writing Prospectus |
| Jun 13, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 12, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 8, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 3, 2023 | FWP | Free Writing Prospectus |
| May 1, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 27, 2023 | 1-K | Acc-no: 0001493152-22-011625 (33 Act) |
| Apr 20, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 5, 2023 | FWP | Free Writing Prospectus |